Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: A gynecologic group study

被引:36
作者
Fracasso, PM
Blessing, JA
Morgan, MA
Sood, AK
Hoffman, JS
机构
[1] Washington Univ, Sch Med, St Louis, MO 63130 USA
[2] Roswell Pk Canc Inst, Gynecol Oncol Grp, Buffalo, NY 14263 USA
[3] Univ Penn, Ctr Canc, Dept Gynecol Oncol, Philadelphia, PA 19104 USA
[4] Univ Iowa Hosp & Clin, Div Gynecol Oncol, Iowa City, IA 52242 USA
[5] Univ Connecticut, Sch Med, Div Gynecol Oncol, Farmington, CT USA
关键词
D O I
10.1200/JCO.2003.03.077
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A phase II study was conducted to determine the efficacy of oxaliplatin therapy in patients with platinum-resistant or refractory epithelial ovarian carcinoma. Materials and Methods: Eligible patients were to receive oxaliplatin 130 mg/m(2) intravenously over 2 hours, every 21 days, until progression of disease or adverse effects prohibited further therapy. Results: Of 25 patients entered onto the study, 23 were eligible and assessable. There were no patients with complete response. One patient (4.3%) achieved a partial response, with a response duration of 6.4 months. Nine patients (39.1%) experienced stable disease, with a median duration of 5.6+ months (range, 1.8 to 13.1 months). The most frequently reported drug-related toxicities were hematologic, gastrointestinal, and neurologic. Conclusion: Oxaliplatin as a single agent has minimal activity in patients with platinum-resistant or refractory ovarian cancer at the dosage and schedule tested. However, future studies of oxaliplatin combined with other active agents in women with platinum-naive or platinum-sensitive epithelial ovarian carcinoma may be indicated.
引用
收藏
页码:2856 / 2859
页数:4
相关论文
共 16 条
[1]   MEDICAL PROGRESS - CANCER OF THE OVARY [J].
CANNISTRA, SA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (21) :1550-1559
[2]  
Chollet P, 1996, ANN ONCOL, V7, P1065
[3]   Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer [J].
Delaloge, S ;
Laadem, A ;
Taamma, A ;
Chouaki, N ;
Cvitkovic, E ;
Pautier, P ;
Misset, JL ;
Lhommé, C .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (06) :569-574
[4]   Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients [J].
Dieras, V ;
Bougnoux, P ;
Petit, T ;
Chollet, P ;
Beuzeboc, P ;
Borel, C ;
Husseini, F ;
Goupil, A ;
Kerbrat, P ;
Misset, JL ;
Bensmaïne, MA ;
Tabah-Fisch, I ;
Pouillart, P .
ANNALS OF ONCOLOGY, 2002, 13 (02) :258-266
[5]  
Extra JM, 1998, SEMIN ONCOL, V25, P13
[6]   Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma:: An investigator-originated compassionate-use experience [J].
Faivre, S ;
Kalla, S ;
Cvitkovic, E ;
Bourdon, O ;
Hauteville, D ;
Dourte, LM ;
Bensmaïne, MA ;
Itzhaki, M ;
Marty, M ;
Extra, JM .
ANNALS OF ONCOLOGY, 1999, 10 (09) :1125-1128
[7]   Cancer statistics, 2002 [J].
Jemal, A ;
Thomas, A ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (01) :23-47
[8]   Oxaliplatin: A review of evolving concepts [J].
Mani, S ;
Graham, MA ;
Bregman, DB ;
Ivy, P ;
Chaney, SG .
CANCER INVESTIGATION, 2002, 20 (02) :246-263
[9]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[10]   Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients [J].
Misset, JL ;
Vennin, P ;
Chollet, P ;
Pouillart, P ;
Laplaige, P ;
Frobert, JL ;
Castera, D ;
Fabro, M ;
Langlois, D ;
Cortesi, E ;
Lucas, V ;
Gamelin, E ;
Laadem, A ;
Otero, J .
ANNALS OF ONCOLOGY, 2001, 12 (10) :1411-1415